— Fundamental Stock Analysis and Report Card
Located in Warsaw, IN, US. Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
Revenue, earnings and profitability.
Strong revenue growth and earnings can attract investors, driving the stock price up. Profitability indicates the company's efficiency and sustainability, which impacts investor confidence. Poor performance in these areas can lead to a decrease in stock price.
Revenue History
Earnings History
Margins
Income & Cash Flow analysis.
An income statement shows what a company earned and spent over a period — revenue at the top, costs and expenses in between, and net income at the bottom. A cash flow statement tracks the actual cash moving in and out, across operations, investing, and financing. Read together, they show whether reported earnings are backed by real cash.
Q1 2026 Total ($) | Q1 2026 Margin (%) | |
|---|---|---|
| Revenue | 2.1b +177.6m +9.3% | |
| Gross Income | 1.5b +151.2m +11.1% | 72% +1.2pp +1.7% |
| EBITDA | 538.3m -11.3m -2.1% | 26% -3.0pp -10.4% |
| Operating Income | 373.2m +80.9m +27.7% | 18% +2.6pp +16.8% |
| Net Income | 238.1m +56.1m +30.8% | 11% +1.9pp +19.7% |
| Earnings Per Share | 1.22 +0.3 +32.6% | |
| Operating Cash Flow | 359.2m -23.6m -6.2% | 17% -2.8pp -14.2% |
| Free Cash Flow | 322.9m -12.9m -3.8% | 15% -2.1pp -12.0% |
| Research & Development | 103.4m -7.2m -6.5% | 5% -0.8pp -14.5% |
What are the analysts saying?
Analyst Consensus aggregates Wall Street recommendations into buy/hold/sell counts, while the Fundamental Scorecard grades the company on six financial ratios (P/B, P/E, D/E, ROA, ROE, DCF) plus an overall score. The two measure different things and can point in different directions.